Authors: Xavier, Pillet
Source: Zenodo (CERN European Organization for Nuclear Research) (article, 2025-12-08)
Field: Chemistry — Organic Chemistry

Étude de Faisabilité : Production Frugale du Au@C60 (Fullerène Endohédrique à l'Or) Résumé FRCe document, produit avec l’assistance de GPT-5.1 Thinking et Gemini 3 Pro, est publié sous la licence Apache 2.0. Il constitue une publication défensive (antériorité) et entre de ce fait dans l’état de la technique lors de sa mise à disposition au public conformément aux textes applicables : EPC Art. 54(2) (European Patent Convention), French IPC Art. L 611-11 (Code de la propriété intellectuelle), 35 U.S.C. §102(a) (United States Patent Act), Loi chinoise sur les brevets Art. 22(5) (中华人民共和国专利法) et Loi japonaise sur les brevets Art. 29(1) (特許法). Le texte décrit une chaîne complète, frugale et industrialisable pour le fullerène endohédrique à l’or Au@C60 : synthèse par arc, purification par centrifugation différentielle, co-production C60/C70, formulations thérapeutiques, dispositifs médicaux, protocoles d’imagerie et d’IA, contrôle de procédé et usine intégrée. Chaque proposition est décrite de manière suffisante (enabling), classée avec des codes IPC et CPC, et accompagnée d’une preuve d’horodatage (RFC 3161 / FreeTSA). Abstract ENThis document, produced with the assistance of GPT-5.1 Thinking and Gemini 3 Pro, is released under the Apache 2.0 licence. It is a voluntary defensive publication (prior art) and therefore enters the prior art upon release under the applicable patent statutes (art. L 611-11 CPI / art. 54(2) CBE), 35 U.S.C. §102(a), Chinese Patent Law Art. 22(5) (中华人民共和国专利法), and Japanese Patent Act Art. 29(1) (特許法). The text discloses a complete, low-cost and scalable chain for the gold endohedral fullerene Au@C60: arc-discharge synthesis, differential centrifugation purification, C60/C70 co-production, therapeutic formulations, medical devices, imaging and AI protocols, process control and integrated plant design. Every proposal is described in an enabling manner, classified with IPC and CPC codes, and accompanied by timestamp proof (RFC 3161 / FreeTSA). Timestamp: 2025-12-08T22:27:28ZSHA-256: b32b6ff97ce875ccf485d7f87b70a945c5c7e0c0740e0c0cd1b23b363a000238 Liste des innovations & classification (IPC ; CPC) 1. Optimized arc reactor for Au@C60 — IPC C01B 31/02 ; CPC C01B 31/0212. Composite graphite–gold–Ni/Cu anode — IPC C22C 5/00 ; CPC C22C 5/063. Continuous arc with moving anode — IPC C01B 31/02 ; CPC C01B 31/0214. Differential centrifugation for Au@C60 — IPC B04B 1/20 ; CPC B04B 1/205. Continuous-flow ultracentrifuge for fullerene — IPC B04B 13/00 ; CPC B04B 13/006. Co-production of Au@C60 and C60/C70 — IPC C01B 31/02 ; CPC C01B 31/0217. Multi-technique QA for Au@C60 — IPC G01N 30/00 ; CPC G01N 30/60248. Intravenous liposomal Au@C60 — IPC A61K 31/7088 ; CPC A61K 31/70889. Oral oily Au@C60 formulation — IPC A61K 31/7088 ; CPC A61K 31/708810. Au@C60 plus mitochondrial antioxidants — IPC A61K 31/00 ; CPC A61K 31/7011. Au@C60–porphyrin PDT/CT conjugate — IPC A61K 49/00 ; CPC A61K 49/004512. Gold core with Au@C60 shell — IPC A61K 49/00 ; CPC A61K 49/004513. Au@C60 implant coating — IPC A61L 27/00 ; CPC A61L 27/5414. Activatable Au@C60 wound dressing — IPC A61L 15/00 ; CPC A61L 15/4415. Au@C60-doped neural electrodes — IPC A61N 1/05 ; CPC A61N 1/37816. CT-guided Au@C60 dosing protocol — IPC A61B 6/03 ; CPC A61B 6/03417. Au@C60-guided radiotherapy planning — IPC A61N 5/10 ; CPC A61N 5/10318. AI platform for Au@C60 optimization — IPC G16H 50/20 ; CPC G16H 50/2019. AI control of arc–centrifuge line — IPC G05D 27/02 ; CPC G05D 27/0220. Closed-loop gold recycling chain — IPC C22B 11/00 ; CPC C22B 11/0021. Au@C60 data and privacy framework — IPC G16H 10/60 ; CPC G16H 10/6022. Integrated EMF and fullerene plant — IPC G06Q 10/30 ; CPC G06Q 10/3023. Chronic anti-ageing Au@C60 regimen — IPC A61P 43/00 ; CPC A61P 43/0024. Ischemia–reperfusion neuroprotection — IPC A61P 9/10 ; CPC A61P 9/1025. Tissue radioprotection with Au@C60 — IPC A61P 35/00 ; CPC A61P 35/0026. Mitochondrial ROS kit using Au@C60 — IPC C12Q 1/02 ; CPC C12Q 1/02327. Au@C60-mediated enzyme biosensor — IPC G01N 27/327 ; CPC G01N 27/32728. FRET ROS sensor Au@C60–fluorophore — IPC G01N 21/64 ; CPC G01N 21/6429. Adaptive clinical trial platform — IPC G16H 50/20 ; CPC G16H 50/2030. Systemic transdermal Au@C60 patch — IPC A61K 9/70 ; CPC A61K 9/7068 KeywordsAu@C60, metallofullerene, arc discharge reactor, helium pressure, differential centrifugation, density gradient, liposomal formulation, mitochondrial targeting, oral formulation, olive oil, combination therapy, porphyrin, photodynamic therapy, CT contrast agent, core shell, hyperthermia, implant coating, wound dressing, neural interface, CT-guided dosing, treatment planning, machine learning, process control, gold recycling, health data, interoperability, industrial plant, antiaging protocol, longevity, stroke therapy, reperfusion, radioprotection, diagnostic kit, mitochondrial ROS, biosensor, enzyme electrode, FRET sensor, oxidative stress, adaptive trial, Bayesian, PKPD, transdermal patch, systemic delivery, nanoformulation, defensive publication Statute ; Trademark ; Patent law ; Research methodology Fullerene Chemistry and Applications ; Graphene and Nanomaterials Applications ; Chemical Reactions and Isotopes